Arrowhead Pharmaceuticals, Inc. (ARWR)
ARWR moved a median of +0.13% 30 minutes after news, and +0.07% by the close. How ARWR actually reacts to news — the realized, point-in-time move the market made, measured across 391 labeled events over the last three years with zero look-ahead.
ARWR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.06% | 53% | 389 |
| 30-min | +0.13% | 52% | 390 |
| 60-min | +0.10% | 53% | 390 |
| to close | +0.07% | 51% | 390 |
| Middle 50% of ARWR reactions | -1.27% to +1.74% |
|---|---|
| Median reaction (30-min) | +0.13% |
| Measured reactions | 391 |
Half of all Arrowhead Pharmaceuticals, Inc. news events land between -1.27% and +1.74% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ARWR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | 0.00% | 40% | -0.39% |
| Coverage initiations | 16 | -0.58% | 38% | +0.88% |
| Rating reiterations | 127 | -0.16% | 45% | -0.14% |
| Price-target raises | 28 | +0.15% | 57% | -0.34% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how ARWR ranks against every other measured name →
That’s how ARWR usually reacts — get an email when it moves on news →Email me when ARWR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ARWR's baseline. Nothing else.
Recent ARWR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers | Press release | Business Wire | +0.34% | +0.36% | |
| Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia | Press release | Business Wire | -0.65% | -0.24% | |
| Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies | Press release | Business Wire | -0.51% | +1.21% | |
| Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia | Press release | Business Wire | -2.38% | -14.74% | |
| Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences | Press release | Business Wire | -0.86% | +1.54% | |
| Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia | Press release | Business Wire | -1.58% | -0.89% | |
| Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress | Press release | Business Wire | -0.74% | -0.05% | |
| People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides | Press release | Business Wire | +0.86% | +2.70% | |
| Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher | Press release | Business Wire | -1.20% | -0.66% | |
| Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results | Press release | Business Wire | -1.20% | -0.66% | |
| Form 10-Q ARROWHEAD PHARMACEUTICAL For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.20% | -0.66% | |
| Form 8-K ARROWHEAD PHARMACEUTICAL For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -1.20% | -0.66% | |
| Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | Business Wire | +0.15% | +2.98% | |
| Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia | Press release | Business Wire | +0.54% | -0.28% | |
| Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia | Press release | Business Wire | +3.10% | +3.79% | |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results | Press release | Business Wire | +0.48% | +2.35% | |
| Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) | Press release | Business Wire | +0.08% | -0.91% | |
| Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars | Press release | Business Wire | -0.23% | -1.42% | |
| Form 8-K ARROWHEAD PHARMACEUTICAL For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +0.40% | +5.87% | |
| Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events | Press release | Business Wire | -1.04% | -4.39% | |
| Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 | Press release | Business Wire | -0.40% | +0.62% | |
| Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress | Press release | Business Wire | -0.25% | +4.95% | |
| Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results | Press release | Business Wire | -4.65% | -4.98% | |
| Form 10-Q ARROWHEAD PHARMACEUTICAL For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.65% | -4.98% | |
| Form 8-K ARROWHEAD PHARMACEUTICAL For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -4.65% | -4.98% | |
| Form S-8 ARROWHEAD PHARMACEUTICAL | SEC filing · Form S-8 | SEC EDGAR | -4.65% | -4.98% | |
| Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals | Press release | Business Wire | +0.27% | -3.00% | |
| Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events | Press release | Business Wire | +1.72% | +3.58% | |
| Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) | Press release | Business Wire | -0.50% | +0.34% | |
| Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe | Press release | Business Wire | -0.20% | -0.51% | |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results | Press release | Business Wire | +0.28% | -1.97% | |
| Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo | Press release | Business Wire | -0.15% | -0.55% | |
| Form 8-K ARROWHEAD PHARMACEUTICAL For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +0.97% | -0.86% | |
| Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events | Press release | Business Wire | -0.73% | +0.38% | |
| Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results | Press release | Business Wire | +1.00% | -1.50% | |
| Form 10-Q ARROWHEAD PHARMACEUTICAL For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.00% | -1.50% | |
| Form 8-K ARROWHEAD PHARMACEUTICAL For: Feb 05 | SEC filing · Form 8-K | SEC EDGAR | +1.00% | -1.50% | |
| Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia | Press release | Business Wire | +1.89% | +0.39% | |
| Form ARS ARROWHEAD PHARMACEUTICAL For: Jan 26 | SEC filing · Form ARS | SEC EDGAR | +1.89% | +0.39% | |
| Form DEF 14A ARROWHEAD PHARMACEUTICAL For: Jan 26 | SEC filing · Form DEF | SEC EDGAR | +1.89% | +0.39% | |
| Form DEFA14A ARROWHEAD PHARMACEUTICAL | SEC filing · Form DEFA14A | SEC EDGAR | +1.89% | +0.39% | |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results | Press release | Business Wire | -0.74% | +2.80% | |
| Form 8-K ARROWHEAD PHARMACEUTICAL For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | -0.84% | |
| Form 8-K ARROWHEAD PHARMACEUTICAL For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | -1.44% | |
| Form 305B2 ARROWHEAD PHARMACEUTICAL | SEC filing · Form 305B2 | SEC EDGAR | +0.76% | -1.44% | |
| Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China | Press release | Business Wire | +1.19% | -0.77% | |
| Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants | Press release | Business Wire | +0.30% | -3.42% | |
| Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition | Press release | Business Wire | +1.64% | -1.75% | |
| Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock | Press release | Business Wire | +1.19% | -0.77% | |
| Form 8-K ARROWHEAD PHARMACEUTICAL For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | +1.19% | -0.77% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ARWR section they belong to.
Where else ARWR is measured.
ARWR earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | 392 | -0.45% | 45% |
| Rubius Therapeutics, Inc. (RUBY) | 392 | -0.32% | 45% |
| Axsome Therapeutics, Inc. (AXSM) | 391 | +0.05% | 52% |
| RA PHARMACEUTICALS (RARX) | 391 | -0.04% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Arrowhead Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled ARWR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 391 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of ARWR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ARWR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.